Valneva SE Competitors
| VALN Stock | USD 5.59 0.03 0.54% |
Pair Correlation for Valneva SE and Iovance Biotherapeutics Summary
Very good diversification
For the present investment horizon, the measured correlation between Valneva SE and Iovance Biotherapeutics stands at 0.07, or Very good diversification. This chart measures the degree of risk overlap between Valneva SE and Iovance Biotherapeutics.
Statistical evidence for mean reversion in Valneva SE's appears through its tendency to revert after extreme valuations. Under mean reversion theory, Valneva SE's price extremes are viewed as temporary dislocations that may self-correct. Mean reversion in Valneva SE's is often observed around historical valuation multiples. Historical data for Valneva SE shows that extreme valuations have tended to normalize over multi-year periods.
Valneva SE Competition Correlation Matrix
Competition correlation for Valneva SE ADR matters because related securities often respond to the same industry, factor, or macro drivers even when their business stories differ. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
Please upgrade your account to get full access to Macroaxis premium features
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Headline performance for Valneva SE Stock may not fully reflect how the business compares across its competitive set. Risk-adjusted metrics help compare Valneva SE's efficiency and downside exposure against peers on a like-for-like basis. These indicators are quantitative in nature and measure volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 3.50 | 1.17 | 0.41 | -0.56 | 1.69 | 4.67 | 66.26 | |||
| ARVN | 2.52 | -0.37 | 0.00 | -0.30 | 0.00 | 6.12 | 16.84 | |||
| AVBP | 2.57 | 0.49 | 0.17 | 0.31 | 2.44 | 6.40 | 18.15 | |||
| ATXS | 1,369 | 695.44 | 364.33 | 7.32 | 0.00 | 3.02 | 45,889 | |||
| GERN | 3.65 | 0.02 | 0.00 | 0.01 | 4.42 | 7.78 | 21.96 | |||
| REPL | 7.43 | 0.18 | 0.01 | 1.59 | 12.55 | 21.20 | 78.92 | |||
| MGTX | 2.93 | 0.44 | 0.11 | 0.24 | 3.61 | 6.75 | 32.97 | |||
| MBX | 3.65 | 0.21 | 0.05 | 0.12 | 4.24 | 8.51 | 20.05 | |||
| DNA | 4.98 | 0.40 | 0.05 | 0.11 | 7.81 | 12.80 | 51.88 | |||
| IOVA | 4.32 | 0.79 | 0.16 | 0.39 | 4.52 | 13.24 | 46.70 |
Peer Comparison: Net Income
Net income is what remains after all costs — operating expenses, interest, taxes, and preferred dividends — are deducted from Valneva SE's total revenue. The relationship between net income growth and revenue growth at Valneva SE reveals whether margin expansion is driving earnings or whether top-line growth is being consumed by rising costs and financing charges.Compare Valneva SE ADR and related stocks such as Day One, Arvinas, and ArriVent BioPharma Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARVN | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -24 M | -41.5 M | -62.1 M | -111.8 M | -183.2 M | -271.9 M | -367.3 M | -198.9 M | -80.8 M | -84.8 M |
| AVBP | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -36.9 M | -69.3 M | -80.5 M | -166.3 M | -149.7 M | -142.2 M |
| GERN | -10.7 M | -96.9 M | -68.9 M | -38.4 M | -35.7 M | 46 K | -29.5 M | -27.9 M | -27 M | -63.6 M | -75.6 M | -116.1 M | -141.9 M | -184.1 M | -174.6 M | -85.8 M | -90.1 M |
| REPL | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -19.7 M | -30.8 M | -52.6 M | -80.9 M | -118 M | -174.3 M | -215.8 M | -247.3 M | -222.6 M | -211.4 M |
| MGTX | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -31 M | -82.9 M | -54.7 M | -58 M | -79.6 M | -129.6 M | -84 M | -147.8 M | -114.2 M | -119.9 M |
| MBX | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -32.6 M | -61.9 M | -87 M | -82.6 M |
| IOVA | -57.1 K | -25.7 M | -3.3 M | -25.4 M | -12 M | -27.7 M | -52.9 M | -92.1 M | -123.6 M | -187.1 M | -259.6 M | -327.8 M | -389.9 M | -444 M | -372.2 M | -391 M | -371.4 M |
Valneva SE Competitive Analysis
A side-by-side look at Valneva SE, Day One, Arvinas, and ArriVent BioPharma highlights where each stock leads or lags. Valneva SE enters the comparison at 530.1 M with 174.7 M in revenue. Profitability is a concern, with a -65.95% net margin and -80.16% return on equity signaling pressure on earnings. Market capitalization diverges sharply here: 2.22 B versus 530.1 M, giving Day One a clear size advantage. Arvinas converts shareholder equity more efficiently at -16.23% versus Valneva SE at -80.16%. Valneva SE is dwarfed by ArriVent BioPharma on market cap at 1.37 B versus 530.1 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Valneva SE Competition Peer Performance Charts
How to Analyze Valneva SE Against Peers
Valneva SE's peer analysis compares Valneva SE with related companies to put valuation, quality, and risk metrics in context. This establishes whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Valneva SE trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Valneva SE leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Valneva SE's beta is lower than the peer group average, meaning its stock tends to swing less during broad market moves. Comparative analysis works best when peers share business drivers, cycle exposure, and capital structure characteristics. For peer comparison, Valneva SE has a market cap of 530.06 million, profit margin of -65.95%.
Valneva SE ADR figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Analyst projections are included when active coverage applies.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board